Press Releases Events & Presentations Press Release Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates August 9, 2023 at 4:06 PM EDT PDF Version Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination expected in 2023 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023. “We are excited about the advancement of 5366, our long-acting helicase-primase inhibitor targeting high-recurrence genital herpes, into GLP toxicology studies and are working quickly to begin clinical trials for this candidate in the first half of next year,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “In parallel, our research organization continues to progress towards a second development candidate nomination, which we expect later this year. We are pleased with the progress of our expanded virology pipeline, for which strong preclinical data from multiple programs were highlighted at recent scientific meetings.” Second Quarter 2023 and Recent Updates Continued IND-enabling studies, including initiation of GLP toxicology studies, for development candidate ABI-5366 (5366), a long-acting helicase-primase inhibitor targeting high-recurrence genital herpesScientific conferences: Presented data highlighting the preclinical characterization of 5366 in one oral presentation and one poster at the 47th Annual International Herpesvirus Workshop (IHW) held July 15-19, 2023Presented five posters at the International Liver CongressTM, the Annual Meeting of the European Association for the Study of the Liver (EASL), held June 21-24, 2023, including preclinical data for the company’s oral, small-molecule hepatitis B virus (HBV)/hepatitis delta virus (HDV) entry inhibitor program and results from in vitro and clinical studies of the next-generation core inhibitors ABI-4334 (4334) and ABI-H3733 (3733)Presented during the Science of HBV Cure meeting held June 2-3, 2023, on 4334 Anticipated Milestones and Events Nominate an additional development candidate from the expanded research portfolio in 2023Complete IND/CTA submission for 5366 and initiate clinical studies in the first half of 2024Advance an additional development candidate into clinical studies by year-end 2024 Upcoming Conferences Three abstracts accepted for presentation at the 2023 International HBV Meeting taking place September 19-23, 2023, in Kobe, Japan, highlighting preclinical and in vitro data for the company’s oral, small-molecule HBV/HDV entry inhibitor program, small-molecule, liver-focused interferon alpha receptor agonist program and next-generation core inhibitor candidate 4334 Second Quarter 2023 Financial Results Cash, cash equivalents and marketable securities were $59.8 million as of June 30, 2023, compared to $73.0 million as of March 31, 2023. Assembly Bio’s cash position is projected to fund operations through the third quarter of 2024.Research and development expenses were $12.5 million for the three months ended June 30, 2023, compared to $17.8 million for the same period in 2022. The decrease is primarily due to prior year preclinical work and start-up costs preparing for the trials for 3733 and 4334 as well as the discontinued development of vebicorvir and ABI-H2158 and decreases in employee and contractor-related expenses.General and administrative expenses were $5.0 million for the three months ended June 30, 2023, compared to $6.8 million for the same period in 2022. The decrease is primarily due to overall cost-saving initiatives.Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022. About Assembly BiosciencesAssembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Forward-Looking StatementsThe information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor and Corporate: Shannon Ryan SVP, Investor Relations, Corporate Affairs and Alliance Management (415) 738-2992 sryan@assemblybio.com Media: Sam Brown Inc.Hannah Hurdle(805) 338-4752ASMBMedia@sambrown.com ASSEMBLY BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands except for share amounts and par value) June 30, December 31, 2023 2022 (Unaudited) ASSETS Current assets Cash and cash equivalents $21,623 $52,418 Marketable securities 38,208 39,192 Accounts receivable from collaboration 342 944 Prepaid expenses and other current assets 3,908 4,413 Total current assets 64,081 96,967 Property and equipment, net 541 743 Operating lease right-of-use (ROU) assets 1,623 3,195 Other assets 332 889 Total assets $ 66,577 $ 101,794 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $904 $2,493 Accrued research and development expenses 2,037 3,122 Other accrued expenses 4,188 7,317 Operating lease liabilities - short-term 1,702 3,364 Total current liabilities 8,831 16,296 Deferred revenue 2,733 2,733 Operating lease liabilities - long-term 64 101 Total liabilities 11,628 19,130 Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 52,450,731 and 48,894,973 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 52 49 Additional paid-in capital 815,588 807,938 Accumulated other comprehensive loss (325) (803)Accumulated deficit (760,366) (724,560)Total stockholders' equity 54,949 82,624 Total liabilities and stockholders' equity $ 66,577 $ 101,794 ASSEMBLY BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(In thousands except for share and per share amounts)(Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses Research and development 12,523 17,792 27,070 34,997 General and administrative 4,965 6,781 9,977 12,738 Total operating expenses 17,488 24,573 37,047 47,735 Loss from operations (17,488) (24,573) (37,047) (47,735) Other income Interest and other income, net 592 112 1,201 183 Total other income 592 112 1,201 183 Net loss $ (16,896) $ (24,461) $ (35,846) $ (47,552) Other comprehensive loss Unrealized gain (loss) on marketable securities 188 (90) 478 (579)Comprehensive loss $ (16,708) $ (24,551) $ (35,368) $ (48,131) Net loss per share, basic and diluted $(0.32) $(0.51) $(0.69) $(0.99)Weighted average common shares outstanding, basic and diluted 52,260,088 48,293,495 51,638,928 48,208,735 Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates August 9, 2023 at 4:06 PM EDT PDF Version Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination expected in 2023 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023. “We are excited about the advancement of 5366, our long-acting helicase-primase inhibitor targeting high-recurrence genital herpes, into GLP toxicology studies and are working quickly to begin clinical trials for this candidate in the first half of next year,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “In parallel, our research organization continues to progress towards a second development candidate nomination, which we expect later this year. We are pleased with the progress of our expanded virology pipeline, for which strong preclinical data from multiple programs were highlighted at recent scientific meetings.” Second Quarter 2023 and Recent Updates Continued IND-enabling studies, including initiation of GLP toxicology studies, for development candidate ABI-5366 (5366), a long-acting helicase-primase inhibitor targeting high-recurrence genital herpesScientific conferences: Presented data highlighting the preclinical characterization of 5366 in one oral presentation and one poster at the 47th Annual International Herpesvirus Workshop (IHW) held July 15-19, 2023Presented five posters at the International Liver CongressTM, the Annual Meeting of the European Association for the Study of the Liver (EASL), held June 21-24, 2023, including preclinical data for the company’s oral, small-molecule hepatitis B virus (HBV)/hepatitis delta virus (HDV) entry inhibitor program and results from in vitro and clinical studies of the next-generation core inhibitors ABI-4334 (4334) and ABI-H3733 (3733)Presented during the Science of HBV Cure meeting held June 2-3, 2023, on 4334 Anticipated Milestones and Events Nominate an additional development candidate from the expanded research portfolio in 2023Complete IND/CTA submission for 5366 and initiate clinical studies in the first half of 2024Advance an additional development candidate into clinical studies by year-end 2024 Upcoming Conferences Three abstracts accepted for presentation at the 2023 International HBV Meeting taking place September 19-23, 2023, in Kobe, Japan, highlighting preclinical and in vitro data for the company’s oral, small-molecule HBV/HDV entry inhibitor program, small-molecule, liver-focused interferon alpha receptor agonist program and next-generation core inhibitor candidate 4334 Second Quarter 2023 Financial Results Cash, cash equivalents and marketable securities were $59.8 million as of June 30, 2023, compared to $73.0 million as of March 31, 2023. Assembly Bio’s cash position is projected to fund operations through the third quarter of 2024.Research and development expenses were $12.5 million for the three months ended June 30, 2023, compared to $17.8 million for the same period in 2022. The decrease is primarily due to prior year preclinical work and start-up costs preparing for the trials for 3733 and 4334 as well as the discontinued development of vebicorvir and ABI-H2158 and decreases in employee and contractor-related expenses.General and administrative expenses were $5.0 million for the three months ended June 30, 2023, compared to $6.8 million for the same period in 2022. The decrease is primarily due to overall cost-saving initiatives.Net loss attributable to common stockholders was $16.9 million, or $0.32 per basic and diluted share, for the three months ended June 30, 2023, compared to $24.5 million, or $0.51 per basic and diluted share, for the same period in 2022. About Assembly BiosciencesAssembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Forward-Looking StatementsThe information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor and Corporate: Shannon Ryan SVP, Investor Relations, Corporate Affairs and Alliance Management (415) 738-2992 sryan@assemblybio.com Media: Sam Brown Inc.Hannah Hurdle(805) 338-4752ASMBMedia@sambrown.com ASSEMBLY BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands except for share amounts and par value) June 30, December 31, 2023 2022 (Unaudited) ASSETS Current assets Cash and cash equivalents $21,623 $52,418 Marketable securities 38,208 39,192 Accounts receivable from collaboration 342 944 Prepaid expenses and other current assets 3,908 4,413 Total current assets 64,081 96,967 Property and equipment, net 541 743 Operating lease right-of-use (ROU) assets 1,623 3,195 Other assets 332 889 Total assets $ 66,577 $ 101,794 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $904 $2,493 Accrued research and development expenses 2,037 3,122 Other accrued expenses 4,188 7,317 Operating lease liabilities - short-term 1,702 3,364 Total current liabilities 8,831 16,296 Deferred revenue 2,733 2,733 Operating lease liabilities - long-term 64 101 Total liabilities 11,628 19,130 Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 52,450,731 and 48,894,973 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 52 49 Additional paid-in capital 815,588 807,938 Accumulated other comprehensive loss (325) (803)Accumulated deficit (760,366) (724,560)Total stockholders' equity 54,949 82,624 Total liabilities and stockholders' equity $ 66,577 $ 101,794 ASSEMBLY BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(In thousands except for share and per share amounts)(Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses Research and development 12,523 17,792 27,070 34,997 General and administrative 4,965 6,781 9,977 12,738 Total operating expenses 17,488 24,573 37,047 47,735 Loss from operations (17,488) (24,573) (37,047) (47,735) Other income Interest and other income, net 592 112 1,201 183 Total other income 592 112 1,201 183 Net loss $ (16,896) $ (24,461) $ (35,846) $ (47,552) Other comprehensive loss Unrealized gain (loss) on marketable securities 188 (90) 478 (579)Comprehensive loss $ (16,708) $ (24,551) $ (35,368) $ (48,131) Net loss per share, basic and diluted $(0.32) $(0.51) $(0.69) $(0.99)Weighted average common shares outstanding, basic and diluted 52,260,088 48,293,495 51,638,928 48,208,735
